Aurinia Pharmaceuticals (AUPH) Stock Statistics & Valuation Metrics

Aurinia Pharmaceuticals has a market cap or net worth of $2.22B. The enterprise value is $2.10B.

Aurinia Pharmaceuticals has 128,601,670 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aurinia Pharmaceuticals’s return on equity (ROE) is 0.49 and return on invested capital (ROIC) is 15.53%.

The current PE Ratio of Aurinia Pharmaceuticals is 7.7. Aurinia Pharmaceuticals’s PEG ratio is 0.00142.

In the last 12 months, Aurinia Pharmaceuticals had revenue of 283.06M and earned 287.20M in profits. Earnings per share was 2.14.

In the last 12 months, operating cash flow was 165.82M and capital expenditures -271.76K, giving a free cash flow of 165.55M billion.

Aurinia Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Aurinia Pharmaceuticals upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Aurinia Pharmaceuticals as a current ratio of 5.25, with Debt / Equity ratio of 12.09%

In the past 12 months, Aurinia Pharmaceuticals has paid -173.04M in taxes.

Aurinia Pharmaceuticals EV to EBITDA ratio is 16.73, with an EV/FCF ratio of 15.79.

Aurinia Pharmaceuticals has $378.78M in cash and marketable securities with $68.64M in debt, giving a net cash position of $310.14M billion.

Gross margin is 89.74%, with operating margin of 37.06%, and net profit margin of 101.47%.

The average price target for Aurinia Pharmaceuticals is $15.67, which is 11.43% higher than the current price. The consensus rating is Moderate Buy